Perspective Therapeutics Inc. (CATX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Perspective Therapeutics Inc. (CATX) has a cash flow conversion efficiency ratio of -0.091x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.47 Million) by net assets ($347.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Perspective Therapeutics Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Perspective Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Perspective Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Perspective Therapeutics Inc. (CATX) stock price for real-time trading data and today's change.
Perspective Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Perspective Therapeutics Inc. ranked by their cash flow conversion efficiency. Review Perspective Therapeutics Inc. (CATX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daodaoquan Grain and Oil Co Ltd
SHE:002852
|
0.260x |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
N/A |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
0.098x |
|
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
NYSE:HQ
|
1.695x |
|
Kaiser China Holding Co Ltd
SHE:002425
|
-0.007x |
|
Zhejiang Jinsheng New Materials Co
SHE:300849
|
0.044x |
|
Wuhan DDMC Culture Co Ltd
SHG:600136
|
-0.085x |
|
Binh Minh Plastics JSC
VN:BMP
|
-0.066x |
Annual Cash Flow Conversion Efficiency for Perspective Therapeutics Inc. (1994–2025)
The table below shows the annual cash flow conversion efficiency of Perspective Therapeutics Inc. from 1994 to 2025. Also see Perspective Therapeutics Inc. assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $207.03 Million | $-82.48 Million | -0.398x | -533.03% |
| 2024-12-31 | $290.67 Million | $-18.29 Million | -0.063x | +87.18% |
| 2023-12-31 | $75.18 Million | $-36.91 Million | -0.491x | -120.42% |
| 2023-06-30 | $54.64 Million | $-12.17 Million | -0.223x | 0.00% |
| 2022-12-31 | $54.64 Million | $-12.17 Million | -0.223x | -77.04% |
| 2022-06-30 | $61.28 Million | $-7.71 Million | -0.126x | 0.00% |
| 2021-12-31 | $61.28 Million | $-7.71 Million | -0.126x | -198.95% |
| 2021-06-30 | $67.41 Million | $-2.84 Million | -0.042x | +81.05% |
| 2020-12-31 | $12.77 Million | $-2.84 Million | -0.222x | +65.09% |
| 2020-06-30 | $5.72 Million | $-3.64 Million | -0.636x | 0.00% |
| 2019-12-31 | $5.72 Million | $-3.64 Million | -0.636x | +3.23% |
| 2019-06-30 | $7.68 Million | $-5.05 Million | -0.657x | 0.00% |
| 2018-12-31 | $7.68 Million | $-5.05 Million | -0.657x | +42.11% |
| 2018-06-30 | $5.03 Million | $-5.71 Million | -1.136x | -110.78% |
| 2017-12-31 | $10.60 Million | $-5.71 Million | -0.539x | 0.00% |
| 2017-06-30 | $10.60 Million | $-5.71 Million | -0.539x | -127.51% |
| 2016-12-31 | $16.40 Million | $-3.88 Million | -0.237x | 0.00% |
| 2016-06-30 | $16.40 Million | $-3.88 Million | -0.237x | -39.74% |
| 2015-12-31 | $20.78 Million | $-3.52 Million | -0.169x | 0.00% |
| 2015-06-30 | $20.78 Million | $-3.52 Million | -0.169x | -25.76% |
| 2014-12-31 | $23.96 Million | $-3.23 Million | -0.135x | 0.00% |
| 2014-06-30 | $23.96 Million | $-3.23 Million | -0.135x | +76.34% |
| 2013-12-31 | $5.37 Million | $-3.06 Million | -0.570x | 0.00% |
| 2013-06-30 | $5.37 Million | $-3.06 Million | -0.570x | -35.37% |
| 2012-12-31 | $5.82 Million | $-2.45 Million | -0.421x | 0.00% |
| 2012-06-30 | $5.82 Million | $-2.45 Million | -0.421x | -12.23% |
| 2011-12-31 | $6.45 Million | $-2.42 Million | -0.375x | 0.00% |
| 2011-06-30 | $6.45 Million | $-2.42 Million | -0.375x | +13.54% |
| 2010-12-31 | $6.20 Million | $-2.69 Million | -0.434x | 0.00% |
| 2010-06-30 | $6.20 Million | $-2.69 Million | -0.434x | -9.39% |
| 2009-12-31 | $9.96 Million | $-3.95 Million | -0.396x | 0.00% |
| 2009-06-30 | $9.96 Million | $-3.95 Million | -0.396x | +19.06% |
| 2008-12-31 | $15.77 Million | $-7.73 Million | -0.490x | 0.00% |
| 2008-06-30 | $15.77 Million | $-7.73 Million | -0.490x | -54.47% |
| 2007-12-31 | $22.72 Million | $-7.20 Million | -0.317x | 0.00% |
| 2007-06-30 | $22.72 Million | $-7.20 Million | -0.317x | +86.94% |
| 2006-12-31 | $2.89 Million | $-7.00 Million | -2.427x | 0.00% |
| 2006-06-30 | $2.89 Million | $-7.00 Million | -2.427x | -276434.01% |
| 2005-06-30 | $11.23 Million | $-9.86K | -0.001x | +99.71% |
| 2004-12-31 | $11.23 Million | $-3.39 Million | -0.301x | -994.03% |
| 2004-06-30 | $-564.20K | $-19.02K | 0.034x | +311.89% |
| 2003-12-31 | $-1.08 Million | $-8.87K | 0.008x | 0.00% |
| 2003-06-30 | $-1.08 Million | $-8.87K | 0.008x | -42.63% |
| 2002-12-31 | $-1.03 Million | $-14.73K | 0.014x | +98.69% |
| 2002-06-30 | $-1.03 Million | $-7.42K | 0.007x | +24.19% |
| 2001-12-31 | $-1.28 Million | $-7.42K | 0.006x | +101.94% |
| 2000-12-31 | $-1.22 Million | $365.34K | -0.298x | -130.95% |
| 1999-12-31 | $-2.14 Million | $275.97K | -0.129x | +42.68% |
| 1999-06-30 | $-1.22 Million | $275.97K | -0.225x | -4087.12% |
| 1998-12-31 | $-2.07 Million | $-11.71K | 0.006x | +3.08% |
| 1998-06-30 | $-2.14 Million | $-11.71K | 0.005x | -99.04% |
| 1997-12-31 | $-1.90 Million | $-1.08 Million | 0.569x | +8.88% |
| 1997-06-30 | $-2.07 Million | $-1.08 Million | 0.523x | -32.96% |
| 1996-12-31 | $-643.46K | $-501.83K | 0.780x | +195.70% |
| 1996-06-30 | $-1.90 Million | $-501.83K | 0.264x | +115.05% |
| 1995-12-31 | $295.71K | $-518.19K | -1.752x | -317.59% |
| 1995-06-30 | $-643.46K | $-518.19K | 0.805x | +145.96% |
| 1994-06-30 | $295.71K | $-518.19K | -1.752x | -- |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more